SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the ...

- Expansion at RP2D is ongoing with an additional 23 patients enrolled to date; expansion data are expected in the first half of 2025 - ...

The poster, #983P, was presented at the Hepatocellular Carcinoma poster session on Sunday, September 16, 2024. The Best ...

This includes: CRC Data from GALAXY (Nature Medicine & ESMO Poster) In this study, 2,240 patients with stage II– IV CRC were monitored using Signatera after curative-intent surgery with a median ...

SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for ...

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical ...

will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

This poster presentation will focus on the analytical validation of a next-generation sequencing (NGS) panel-based extrachromosomal DNA (ecDNA) detection device. This innovative device has been ...